Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05123599




Registration number
NCT05123599
Ethics application status
Date submitted
16/11/2021
Date registered
17/11/2021
Date last updated
22/05/2024

Titles & IDs
Public title
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection
Scientific title
A Phase 1b, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Treatment With JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, HBeAg-negative Participants With Chronic Hepatitis B Virus Infection
Secondary ID [1] 0 0
2020-005584-30
Secondary ID [2] 0 0
CR109042
Universal Trial Number (UTN)
Trial acronym
OSPREY
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatitis B, Chronic 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - JNJ-73763989
Other interventions - JNJ-64300535
Treatment: Drugs - ETV monohydrate
Treatment: Drugs - Tenofovir disoproxil
Treatment: Drugs - TAF

Experimental: JNJ-73763989 plus JNJ-64300535 plus Nucleos(t)ide Analogs (NAs) - Participants will receive JNJ-73763989 subcutaneous (SC) injection once every 4 weeks (q4w), NA (either Entecavir monohydrate [ETV], Tenofovir disoproxil or Tenofovir alafemide [TAF]) oral tablets once daily (qd) and JNJ-64300535 intramuscular (IM) injection q4w. From day 187, participants will receive treatment with NA oral tablets qd up to Week 36.


Treatment: Drugs: JNJ-73763989
JNJ-73763989 injection will be administered subcutaneously.

Other interventions: JNJ-64300535
JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.

Treatment: Drugs: ETV monohydrate
ETV monohydrate film-coated tablets will be administered orally.

Treatment: Drugs: Tenofovir disoproxil
Tenofovir disoproxil film-coated tablets will be administered orally.

Treatment: Drugs: TAF
TAF film-coated tablets will be administered orally.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants with a Reduction of at Least 2 log10 International Units per Milliliter (IU/mL) in Hepatitis B Surface Antigen (HBsAg) Levels from Baseline to Week 36
Timepoint [1] 0 0
Baseline to Week 36 (end of study intervention)
Secondary outcome [1] 0 0
Percentage of Participants with at Least 3-fold Increase in Hepatitis B Virus (HBV)- Specific T-Cell Response Against Vaccine Antigen HBV Core and/or Pol
Timepoint [1] 0 0
From Day 103 up to Week 84
Secondary outcome [2] 0 0
Percentage of Responders Against Vaccine Antigen HBV Core and/or Pol
Timepoint [2] 0 0
Week 28
Secondary outcome [3] 0 0
Percentage of Participants with Adverse Events (AEs)
Timepoint [3] 0 0
Up to Week 84
Secondary outcome [4] 0 0
Percentage of Participants with Serious AEs
Timepoint [4] 0 0
Up to Week 84
Secondary outcome [5] 0 0
Percentage of Participants with Abnormalities in Clinical Laboratory Tests
Timepoint [5] 0 0
Up to Week 84
Secondary outcome [6] 0 0
Percentage of Participants with Abnormalities in 12- lead Electrocardiograms (ECGs)
Timepoint [6] 0 0
Up to Week 84
Secondary outcome [7] 0 0
Percentage of Participants with Abnormalities in Vital Signs
Timepoint [7] 0 0
Up to Week 84
Secondary outcome [8] 0 0
Percentage of Participants with Abnormalities in Physical Examinations
Timepoint [8] 0 0
Up to Week 84
Secondary outcome [9] 0 0
Percentage of Participants with Solicited Local AEs for JNJ-64300535 up to 7 Days Post Each Vaccination
Timepoint [9] 0 0
7 days post each vaccination (Up to Day 194)
Secondary outcome [10] 0 0
Percentage of Participants with Solicited Systematic AEs for JNJ-64300535 up to 7 Days Post Each Vaccination
Timepoint [10] 0 0
7 days post each vaccination (Up to Day 194)
Secondary outcome [11] 0 0
Change from Baseline Over Time in HBsAg Levels
Timepoint [11] 0 0
Baseline up to Week 84
Secondary outcome [12] 0 0
Change from Start of Vaccination Over Time in HBsAg Levels
Timepoint [12] 0 0
From Day 103 up to Week 84
Secondary outcome [13] 0 0
Percentage of Participants with HBsAg, HBV Deoxyribonucleic Acid (DNA) and Alanine Aminotransferase (ALT) Levels Below/Above Different Cut-offs
Timepoint [13] 0 0
Up to Week 84
Secondary outcome [14] 0 0
Percentage of Participants with HBsAg Seroclearance
Timepoint [14] 0 0
Up to Week 84
Secondary outcome [15] 0 0
Percentage of Participants with HBsAg Seroconversion
Timepoint [15] 0 0
Up to Week 84
Secondary outcome [16] 0 0
Time to Achieve HBsAg Seroclearance
Timepoint [16] 0 0
Up to Week 84
Secondary outcome [17] 0 0
Time to Achieve HBsAg Seroconversion
Timepoint [17] 0 0
Up to Week 84
Secondary outcome [18] 0 0
Percentage of Participants Meeting Nucleos(t)ide Analog (NA) Treatment Completion Criteria
Timepoint [18] 0 0
Week 38 and Week 40
Secondary outcome [19] 0 0
Percentage of Participants with Virological Breakthrough
Timepoint [19] 0 0
Up to Week 36
Secondary outcome [20] 0 0
Percentage of Participants with HBsAg Seroclearance at Week 60 and Week 84
Timepoint [20] 0 0
Weeks 60 and 84
Secondary outcome [21] 0 0
Percentage of Participants with HBV DNA <LLOQ at Week 60 and Week 84
Timepoint [21] 0 0
Weeks 60 and 84
Secondary outcome [22] 0 0
Percentage of Participants with Viral Flares
Timepoint [22] 0 0
From Week 36 to Week 84
Secondary outcome [23] 0 0
Percentage of Participants with Biochemical Flares
Timepoint [23] 0 0
From Week 36 to Week 84
Secondary outcome [24] 0 0
Number of TriGrid Delivery System (TDS)-Intramuscular (IM) version 2.0 Device Fault Conditions by Type
Timepoint [24] 0 0
From Day 103 to Day 187

Eligibility
Key inclusion criteria
- Participants must be medically stable based on physical examination, medical history,
vital signs, and 12-lead electrocardiogram (ECG) performed at screening. Any
abnormalities, must be consistent with the underlying illness in the study population
and this determination must be recorded in the participant's source documents and
initialed by the investigator

- Participants must have a body mass index (BMI; weight in kilograms [kg] divided by the
square of height in meters) between 19.0 and 32.0 kilograms per meter square (kg/m^2),
extremes included

- A woman of childbearing potential must have a negative highly sensitive serum
pregnancy test (beta-human chorionic gonadotropin) at screening and a negative urine
pregnancy test on Day 1 before the first dose of study intervention

- Participants must have chronic hepatitis B virus (HBV) infection. HBV infection must
be documented by serum hepatitis B surface antigen (HBsAg) positivity at screening. In
addition, chronicity must be documented by any of the following, at least 6 months
prior to screening: serum HBsAg positivity, hepatitis B e antigen (HBeAg) positivity
or HBV deoxyribonucleic acid (DNA) positivity, alanine aminotransferase (ALT)
elevation above upper limit of normal (ULN) without another cause than HBV infection,
documented transmission event. If none of the above are available, the following ways
of documenting chronicity are acceptable at the time of screening: liver biopsy with
changes consistent with chronic HBV, or absence of marker for acute HBV infection such
as positive immunoglobulin M (IgM) anti- hepatitis B surface protein (HBs) and anti-
hepatitis B core protein (HBc) antibodies. Virologically suppressed participants
should: a) be HBeAg-negative and anti- hepatitis B e (HBe) positive, b) be on stable
HBV treatment, defined as currently receiving nucleos(t)ide analog (NA) treatment for
at least 6 months prior to screening and having been on the same NA treatment regimen
(at the same dose) as used in this study for at least 3 months at the time of
screening, c) have serum HBV deoxyribonucleic acid (DNA) less than (<) 60
International units per milliliter (IU/mL) on 2 sequential measurements at least 6
months apart (one of which is at screening), and d) have documented ALT values <2.0*
ULN on 2 sequential measurements at least 6 months apart (one of which is at
screening)

- Participants must have: a) Fibroscan liver stiffness measurement less than or equal to
(<=) 9.0 kPa within 6 months prior to screening or at the time of screening, or b) If
a Fibroscan result is not available: a liver biopsy result classified as Metavir F0-F2
within 1 year prior to screening
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- History or evidence of clinical signs or symptoms of hepatic decompensation, including
but not limited to: portal hypertension, ascites, hepatic encephalopathy, esophageal
varices

- Participants with a history of malignancy within 5 years before screening (exceptions
are squamous and basal cell carcinomas of the skin and carcinoma in situ of the
cervix, or malignancy, which are considered cured with minimal risk of recurrence)

- Participants with any history of or current clinically significant skin disease
requiring regular or periodic treatment

- Participants with clinically relevant alcohol or drug abuse within 12 months of
screening

- Participants who had major surgery (example, requiring general anesthesia), excluding
diagnostic surgery, within 12 weeks before screening; or will not have fully recovered
from surgery; or have surgery planned during the time of expected participation in the
study

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/12/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
2/08/2024
Actual
Sample size
Target
Accrual to date
Final
24
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Edegem
Country [2] 0 0
France
State/province [2] 0 0
Clichy
Country [3] 0 0
France
State/province [3] 0 0
Lyon
Country [4] 0 0
Italy
State/province [4] 0 0
Milano
Country [5] 0 0
Italy
State/province [5] 0 0
Pisa
Country [6] 0 0
New Zealand
State/province [6] 0 0
Auckland
Country [7] 0 0
Poland
State/province [7] 0 0
Myslowice
Country [8] 0 0
Spain
State/province [8] 0 0
Barcelona
Country [9] 0 0
Spain
State/province [9] 0 0
Santander
Country [10] 0 0
Taiwan
State/province [10] 0 0
Kaohsiung City
Country [11] 0 0
Taiwan
State/province [11] 0 0
Tao Yuan
Country [12] 0 0
United Kingdom
State/province [12] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy of the study intervention based on
hepatitis B surface antigen (HBsAg) levels.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05123599
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries